Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells
Open Access
- 17 April 2020
- Vol. 11 (4), 439
- https://doi.org/10.3390/genes11040439
Abstract
We have previously developed an rAAV2/HBoV1 vector in which a recombinant adeno-associated virus 2 (rAAV2) genome is pseudopackaged into a human bocavirus 1 (HBoV1) capsid. Recently, the production of rAAV2/HBoV1 in human embryonic kidney (HEK) 293 cells has been greatly improved in the absence of any HBoV1 nonstructural proteins (NS). This NS-free production system yields over 16-fold more vectors than the original production system that necessitates NS expression. The production of rAAV with infection of baculovirus expression vector (BEV) in the suspension culture of Sf9 insect cells is highly efficient and scalable. Since the replication of the rAAV2 genome in the BEV system is well established, we aimed to develop a BEV system to produce the rAAV2/HBoV1 vector in Sf9 cells. We optimized the usage of translation initiation signals of the HBoV1 capsid proteins (Cap), and constructed a BEV Bac-AAV2Rep-HBoV1Cap, which expresses the AAV2 Rep78 and Rep52 as well as the HBoV1 VP1, VP2, and VP3 at the appropriate ratios. We found that it is sufficient as a trans helper to the production of rAAV2/HBoV1 in Sf9 cells that were co-infected with the transfer Bac-AAV2ITR-GFP-luc that carried a 5.4-kb oversized rAAV2 genome with dual reporters. Further study found that incorporation of an HBoV1 small NS, NP1, in the system maximized the viral DNA replication and thus the rAAV2/HBoV1 vector production at a level similar to that of the rAAV2 vector in Sf9 cells. However, the transduction potency of the rAAV2/HBoV1 vector produced from BEV-infected Sf9 cells was 5–7-fold lower in polarized human airway epithelia than that packaged in HEK293 cells. Transmission electron microscopy analysis found that the vector produced in Sf9 cells had a high percentage of empty capsids, suggesting the pseudopackage of the rAAV2 genome in HBoV1 capsid is not as efficient as in the capsids of AAV2. Nevertheless, our study demonstrated that the rAAV2/HBoV1 can be produced in insect cells with BEVs at a comparable yield to rAAV, and that the highly efficient expression of the HBoV1 capsid proteins warrants further optimization.Funding Information
- National Institute of Allergy and Infectious Diseases (AI150877 and AI139572)
- Cystic Fibrosis Foundation (YAN19XX0)
This publication has 67 references indexed in Scilit:
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BThe New England Journal of Medicine, 2011
- Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α1-Antitrypsin: Interim ResultsHuman Gene Therapy, 2011
- Reproducible High Yields of Recombinant Adeno-Associated Virus Produced Using Invertebrate Cells in 0.02- to 200-Liter CulturesHuman Gene Therapy, 2011
- Characterization of the gene expression profile of human bocavirusVirology, 2010
- A viral assembly factor promotes AAV2 capsid formation in the nucleolusProceedings of the National Academy of Sciences of the United States of America, 2010
- A Simplified Baculovirus-AAV Expression Vector System Coupled With One-step Affinity Purification Yields High-titer rAAV Stocks From Insect CellsMolecular Therapy, 2009
- Vision 1 Year after Gene Therapy for Leber's Congenital AmaurosisThe New England Journal of Medicine, 2009
- Producing Recombinant Adeno-Associated Virus in Foster Cells: Overcoming Production Limitations Using a Baculovirus–Insect Cell Expression StrategyHuman Gene Therapy, 2009
- An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Production of recombinant adeno-associated vectors using two bioreactor configurations at different scalesJournal of Virological Methods, 2007